FY2026 EPS Estimates for MeiraGTx Boosted by HC Wainwright

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Equities researchers at HC Wainwright lifted their FY2026 EPS estimates for MeiraGTx in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.36 for the year, up from their previous estimate of ($1.89). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2026 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($1.45) EPS.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Thursday, August 13th. The company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $2.17. The business had revenue of $321.43 million during the quarter, compared to analysts’ expectations of $0.70 million. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%.

Several other research firms have also issued reports on MGTX. Wall Street Zen raised MeiraGTx from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a research note on Friday, July 17th. Royal Bank Of Canada raised their target price on shares of MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Piper Sandler boosted their target price on shares of MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Finally, Zacks Research raised shares of MeiraGTx from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $26.17.

MeiraGTx Price Performance

Shares of NASDAQ MGTX opened at $13.89 on Monday. The stock has a market capitalization of $1.33 billion, a PE ratio of 19.56 and a beta of 1.23. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.76 and a quick ratio of 3.76. The business has a fifty day moving average price of $12.28 and a two-hundred day moving average price of $9.92. MeiraGTx has a fifty-two week low of $6.62 and a fifty-two week high of $15.35.

Insider Activity

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of MeiraGTx stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total value of $859,320.00. Following the transaction, the chief executive officer owned 1,325,695 shares in the company, valued at $18,374,132.70. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $14.80, for a total value of $409,353.20. Following the transaction, the insider directly owned 640,846 shares of the company’s stock, valued at approximately $9,484,520.80. The trade was a 4.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 145,659 shares of company stock worth $1,969,233. Insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On MeiraGTx

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Algert Global LLC boosted its position in MeiraGTx by 13.9% during the 2nd quarter. Algert Global LLC now owns 11,700 shares of the company’s stock worth $158,000 after buying an additional 1,430 shares during the period. BNP Paribas Financial Markets increased its position in MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after acquiring an additional 1,466 shares during the period. Kennedy Capital Management LLC increased its position in MeiraGTx by 2.2% in the 4th quarter. Kennedy Capital Management LLC now owns 70,738 shares of the company’s stock valued at $562,000 after acquiring an additional 1,495 shares during the period. Russell Investments Group Ltd. raised its stake in shares of MeiraGTx by 4.3% during the third quarter. Russell Investments Group Ltd. now owns 82,844 shares of the company’s stock valued at $682,000 after acquiring an additional 3,452 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of MeiraGTx by 11.0% during the fourth quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock valued at $302,000 after acquiring an additional 3,766 shares during the last quarter. 67.48% of the stock is owned by institutional investors.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.